Ipsen, a Paris-based drugmaker, is removing its cancer drug Tazverik (tazemetostat) from the U.S. market because of safety concerns. An ongoing Tazverik clinical trial has reported adverse events of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results